Boehringer Signs Deal for Owkin AI, Joining Astra and Sanofi

Boehringer Ingelheim has entered into a collaboration to utilize Owkin’s artificial intelligence platform for the research and development of new oncology and immunology treatments. This partnership joins existing agreements Owkin holds with AstraZeneca and Sanofi, marking a broader industry shift toward integrating machine learning models to accelerate drug discovery timelines.